Medix Biochemica Acquires IVD Raw Materials Producer Bioresource Technology

By HospiMedica International staff writers

[21 Jun 2022]
Image: Medix Biochemica has broadened its capabilities in diagnostic base matrices through the acquisition of BRT (Photo courtesy of Pexels)

Medix Biochemica (Espoo, Finland) has acquired 100% of the shares of Bioresource Technology (BRT, Weston, FL, USA) to broaden its base matrix capabilities and further strengthen its local presence in the US market. As a result of this partnership, Medix will provide its customers with a comprehensive offering of raw materials for their in vitro diagnostics (IVD) quality control products.


BRT is a leading provider of high-quality base matrices and other critical raw materials to many of the largest IVD manufacturers across the world, with a focus on manufacturing immunoassay, clinical chemistry and molecular diagnostic assay and QC materials. BRT’s organization and operations will form a significant part of Medix’s IVD Biomaterials Business Unit, which also comprises manufacturing of native antigens, enzymes, proteins and biological.


“Together, we have the potential to broaden our offering to IVD companies across the globe,” said Steve Ferguson, CEO of Medix Biochemica. “There is an excellent complementary offering between our portfolios, enabling Medix Biochemica to be a comprehensive partner for IVD companies requiring quality raw materials for QC products. With our complete offering of biological samples, processed plasma, base matrices, native enzymes, proteins, antibodies or antigens and our depth of expertise, we can dramatically reduce time to market for IVD companies whatever their need. Our vision is to be the first-choice partner for the IVD industry, and the team at BRT takes us one step closer.”


“We are excited about joining Medix Biochemica,” addd Derik Reichenbach, President of BRT. “Building long-term relationships with our customers have always been key to our success and together with Medix Biochemica’s global team, we are now able to reach even more IVD customers across the globe. We are very much looking forward to contributing to the strong growth of Medix Biochemica.”


Related Links:
Medix Biochemica 
Bioresource Technology